Not recruiting
Malignant melanoma stage IV+1
Not recruitingStudy of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies
Registered drugNo placebo
Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies
Registered drugNo placebo
- Disease:Malignant melanoma stage IVMalignant melanoma stage III
- Substances:CemiplimabEnomimeran+3
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Cemiplimab



